Open-Label Safety Study of ADS-5102 in PD Patients With LID
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral
capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients
with Levodopa Induced Dyskinesia (LID).